Scotiabank downgraded Myriad Genetics (MYGN) to Sector Perform from Outperform with a $6 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $4 from $9 at BofA
- Myriad Genetics price target lowered to $7 from $16 at Morgan Stanley
- Myriad Genetics price target lowered to $9 from $12.50 at Piper Sandler
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
- Myriad Genetics Faces Challenges Amid Prenatal Testing Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue